Recent Disclosures


The date of the hearing on the motions for summary judgement on the trade secret claims between Veeva and IQVIA has been set for January 9, 2025. As of December 13, 2024, we do not have a trial date set as we do not expect the trial to begin in February 2025, as previously scheduled.
There were no significant changes to our employee population or employee compensation programs during fiscal year 2024 that materially affected our pay ratio disclosure. Accordingly, for purposes of calculating the CEO pay ratio in our annual proxy statement, we used the same median employee that we used for the CEO pay ratio calculation in our 2023 proxy statement, as is permitted by the applicable rules. That employee’s fiscal year 2024 compensation decreased as compared to the prior fiscal year as a result of a one-time event in fiscal year 2024 that was specific to the individual employee. Consequently, on a voluntary basis, we are providing what the total fiscal year 2024 compensation of that employee would have been had the one-time event not occurred. That amount is approximately $167,000.